KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Operations (2016 - 2025)

Historic Cash from Operations for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$92.6 million.

  • CRISPR Therapeutics AG's Cash from Operations fell 8499.13% to -$92.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$345.0 million, marking a year-over-year decrease of 14165.04%. This contributed to the annual value of -$345.0 million for FY2025, which is 14165.04% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Cash from Operations is -$92.6 million, which was down 8499.13% from -$84.6 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Cash from Operations ranged from a high of $807.0 million in Q2 2021 and a low of -$142.0 million during Q2 2022
  • Its 5-year average for Cash from Operations is -$35.2 million, with a median of -$94.1 million in 2024.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Cash from Operations surged by 285624.85% in 2021 and then crashed by 16824.82% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Cash from Operations stood at -$86.0 million in 2021, then crashed by 31.72% to -$113.3 million in 2022, then increased by 15.23% to -$96.1 million in 2023, then skyrocketed by 47.92% to -$50.0 million in 2024, then crashed by 84.99% to -$92.6 million in 2025.
  • Its Cash from Operations stands at -$92.6 million for Q4 2025, versus -$84.6 million for Q3 2025 and -$113.9 million for Q2 2025.